Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641177 | 0.93 | EDNRA (0.46) | EDNRAEDNRB | |
| SCHEMBL8684591 | 0.82 | EDNRA (0.35) | EDNRAEDNRB | |
| SCHEMBL6646134 | 0.81 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL6638557 | 0.81 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL6643655 | 0.81 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL6696366 | 0.77 | EDNRA (0.66) | EDNRAEDNRB | |
| SCHEMBL29281002 | 0.76 | TSHR (0.34) | EDNRA | |
| SCHEMBL30296047 | 0.76 | EDNRB (0.42) | EDNRAEDNRB | |
| SCHEMBL6641912 | 0.75 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL6641914 | 0.75 | EDNRA (0.51) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | POLNIASZEK RICHARD P (US) | 2004-03-25 | — | — | US | claimed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | claimed |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | POLNIASZEK RICHARD P (US) | 2004-03-25 | — | — | US | disclosed |
| US-6639082-B2 | Cycloboronate intermediates; endothelin antagonists useful, inter alia, for the treatment of hypertension. | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | REN, STS, CYP4X1 | EDNRA 11/4885EDNRB 12/4885 |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.